Chronic fatigue syndrome

British Medical Journal

Volumn 320, Issue 7230, 2000, Pages 292-296

  Reid, Steven ^a   Chalder, Trudie ^a   Cleare, Anthony ^a   Hotopf, Matthew ^a   Wessely, Simon ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; CORTICOSTEROID; FLUDROCORTISONE; FLUOXETINE; HYDROCORTISONE; IMMUNOGLOBULIN G; MAGNESIUM; NICOTINAMIDE ADENINE DINUCLEOTIDE; PRIMROSE OIL;

ADRENAL SUPPRESSION; ARTHRALGIA; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; META ANALYSIS; MORBIDITY; NEUTROPENIA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REST; SHORT SURVEY; SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANTIDEPRESSIVE AGENTS; BED REST; COGNITIVE THERAPY; EXERCISE THERAPY; FATIGUE SYNDROME, CHRONIC; HUMANS; IMMUNOTHERAPY;

EID: 0034728235     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (40)

1. 1 Fukuda K, Straus S, Hickie I, Sharpe M, Dobbins J, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994;121:953-9.
2. 2 Sharpe M, Archard LC, Banatvala JE. A report - chronic fatigue syndrome: guidelines for research. J R Soc Med 1991;84:118-21.
3. 3 Wessely S, Chalder T, Hirsch S, Wallace P, Wright D. The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: a prospective primary care study. Am J Public Health 1997;87:1449-55.
4. 4 Steele L, Dobbins JG, Fukuda K, Reyes M, Randall B, Koppelman M, et al. The epidemiology of chronic fatigue in San Francisco. Am J Med 1998;105(suppl 3A):83-90S.
5. 5 Lawrie SM, Pelosi AJ. Chronic fatigue syndrome in the community: prevalence and associations. Br J Psychiatry 1995;166:793-7.
6. 6 Wessely S.The epidemiology of chronic fatigue syndrome. Epidemiological Reviews 1995;17:1-13.
7. 7 Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic review. Q J Med 1997;90:223-33.
8. 8 Stewart AD, Hays RD, Ware JE. The MOS short-form general health survey. Medical Care 1988;26:724-32.
9. 9 Karnofsky DA, Burchenal JH, MacLead CM, eds. The clinical evaluation of chemotherapeutic agents in cancer. New York: Columbia University Press, 1949:191-206.
10. 10 Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh JK. An inventory for measuring depression. Arch Gen Psych 1961;4:561-71.
11. 11 Bergner M, Bobbit RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. Medical Care 1981;19:787-805.
12. 12 Vercoulen J, Swanink C, Zitman F. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996;347:858-61.
13. 13 Wearden AJ, Morriss RK, Mullis R, Strickland PL, Pearson DJ, Appleby L, et al. Randomised, double-blind, placebo controlled treatment trial of fluoxetine and a graded exercise programme for chronic fatigue syndrome. Br J Psychiatry 1998;172:485-90.
14. 14 Natelson BH, Cheu J, Pareja J, Ellis SP, Poliscastro T, Findley TW. Randomised, double blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. Psychopharmacology 1996;124:226-30.
15. 15 Behan PO, Hannifah H. 5-HT reuptake inhibitors in CES. J Immunol Immunopharmacology 1995;15:66-9.
16. 16 Peterson PK, Pheley A, Schroeppel J, Schenck C, Marshall P, Kind A, et al. A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome. Arch Intern Med 1998;158:908-14.
17. 17 McKenzie R, O'Fallon A, Dale J, Demitrack M, Sharma G, Deloria M. et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome. JAMA 1998;280:1061-6.
18. 18 Cleare AJ, Heap E, Malhi G, Wessely S, O'Keane V, Miell J. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet 1999;353:455-8.
19. 19 Bou-Holaigah I, Rowe P, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995;274:961-7.
20. 20 Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991;73:1224-34.
21. 21 Fulcher KY, White PD. A randomised controlled trial of graded exercise therapy in patients with the chronic fatigue syndrome. BMJ 1997;314:1647-52.
22. 22 Sandler H, Vernikos J. Inactivity: physiological effects. London: Academic Press, 1986.
23. 23 Dalrymple W. Infectious mononucleosis: 2. Relation of bed rest and activity to prognosis. Postgrad Med 1961;35:345-9.
24. 24 Cox IM, Campbell MJ, Dowson D. Red blood cell magnesium and chronic fatigue syndrome. Lancet 1991;337:757-60.
25. 25 Behan PO, Behan WMH, Horrobin D. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol Scand 1990;82:209-16.
26. 26 Warren G, McKendrick M, Peet M. The role of essential fatty acids in chronic fatigue syndrome. Acta Neurol Scand 1999;99:112-6.
27. 27 Clague JE, Edwards RHT, Jackson MJ. Intravenous magnesium loading in chronic fatigue syndrome. Lancet 1992;340:124-5.
28. 28 Hinds G, Bell NP, McMaster D, McCluskey DR. Normal red cell magnesium concentrations and magnesium loading tests in patients with chronic fatigue syndrome. Ann Clin Biochem 1994;31:459-61.
29. 29 Swanink CM, Vercoulen JH, Bleijenberg G, Fennis JF, Galama JM, van der Meer JW. Chronic fatigue syndrome: a clinical and laboratory study with a well matched control group. J Intern Med 1995;237:499-506.
30. 30 Peterson PK, Shepard J, Macres M, Schenck C, Crosson J, Rechtman D, et al. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med 1990;89:554-60.
31. 31 Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am J Med 1990;89:561-8.
32. 32 Vollmer-Conna C, Hickie I, Hadzi-Pavlovic D, Tymms K, Wakefield D, Dwyer J, et al. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome. Am J Med 1997;103:38-43.
33. 33 Rowe KS. Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents. J Psychiatr Res 1997;31:133-47.
34. 34 See DM, Tilles JG. Alpha interferon treatment of patients with chronic fatigue syndrome. Immunological Investigations 1996;25:153-64.
35. 35 Lloyd A, Hickie I, Brockman A, Hickie C, Wilson A, Dwyer J, et al. Immunologic and psychological therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial. Am J Med 1993;94: 197-203.
36. 36 Steinberg P, McNutt BE, Marshall P, Schenck C, Lurie N, Pheley A, et al. Double-blind placebo-controlled study of efficacy of oral terfenadine in the treatment of chronic fatigue syndrome. J Allergy Clin Immunol 1996;97:119-26.
37. 37 Price JR, Couper, J. Cognitive behaviour therapy for CFS. In: Cochrane Collaboration. Cochrane Library. Issue 4. Oxford: Update Software, 1998.
38. 38 Sharpe M, Hawton K, Simkin S, Surawy C, Hackmann A, Klimes I, et al. Cognitive behaviour therapy for chronic fatigue syndrome: a randomised controlled trial. BMJ 1996;312:22-6.
39. 39 Deale A, Chalder T, Marks I, Wessely S. Cognitive behaviour therapy for chronic fatigue syndrome: a randomized controlled trial. Am J Psychiatry 1997;154:408-14.
40. 40 Forsyth LM, Preuss HG, MacDowell AL, Chiazze L Jr. Birkmayer GD, Bellanti JA. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol 1999;82:185-91.